ClinicalTrials.gg
CompletedNCT04483973Updated Jun 29, 2026Results posted

SPI-1005 Treatment in Severe COVID-19 Patients

A Phase 2 interventional study of Ebselen and Placebo in Covid19, Coronavirus and Coronavirus Infection, sponsored by Sound Pharmaceuticals, Incorporated. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Sound Pharmaceuticals, Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
988th of 1,321
25 · median 91
Started
2021
with 503 others
Phase 2
349 of 1,859
14 open now
Registered
517th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 988th largest by enrollment of the 1,321 interventional ones that give a count, is one of 504 that started in 2021, is one of 349 in phase 2, and was the 517th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID-19 disease.

03

Conditions studied

  • Covid19
  • Coronavirus
  • Coronavirus Infection
  • Corona Virus Infection

Keywords

  • ebselen
  • SPI-1005
  • COVID-19
  • Covid
  • SARS-COV-2
  • Mpro
  • main protease
  • PLpro
  • papain-like protease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years of age
  • Positive nCoV2 PCR test by nasopharyngeal, oral, saliva, or respiratory sample
  • Clinical signs, symptoms, and respiratory status consistent with severe COVID-19
  • Score of 5-7 on the WHO Ordinal Scale
  • Onset of severe COVID-19 symptoms ≤7 days of study enrollment
  • Subject is in-patient at time of randomization to study treatment
  • Subject or legally authorized representative is willing and able to provide , and agrees for subject to comply with planned study procedures including reproductive requirements

Exclusion criteria

Exclusion Criteria:

  • Female patients who are pregnant or breastfeeding.
  • Participation in another interventional drug or device study concurrently or within 30 days prior to study consent.
  • Patients with impaired hepatic or renal function.
  • Subject has any other illness or condition that, in the opinion of the investigator, would prohibit the subject from participating.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Oral administration of matching placebo BID for 14 days, with 30-day follow-up

    Drug: Placebo

  • Active comparator
    SPI-1005 400 mg BID

    Oral administration of SPI-1005 400 mg BID for 14 days, with 30-day follow-up

    Drug: Ebselen

Interventions

  • Glutathione peroxidase mimetic

    Also known as: SPI-1005

  • DrugPlacebo

    Matching placebo containing excipients

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-related Adverse Events

    Number of participants with adverse events, categorized by Common Terminology Criteria for Adverse Events (CTCAE) grading for severity.

    Time frame: 30 days

Secondary outcomes

  1. WHO Ordinal Scale

    Clinical outcome assessed by WHO Ordinal Scale for Clinical Improvement. Scale is 0-8 where higher score is worse outcome.

    Time frame: 30 days

07

Results

Posted Jun 29, 2026

Participant flow

Participant flow — Overall Study
MilestonePlaceboSPI-1005 400 mg BID
Started916
Completed610
Not completed36
Withdrew: Death14
Withdrew: Withdrawal by subject20
Withdrew: Lost to follow-up01
Withdrew: Subject non-compliant with study drug dosing01

Outcome measures

PrimaryNumber of Participants With Treatment-related Adverse Events

Number of participants with adverse events, categorized by Common Terminology Criteria for Adverse Events (CTCAE) grading for severity.

Time frame:
30 days
Reported as:
Number · participants
Number of Participants With Treatment-related Adverse Events
participantsPlaceboSPI-1005 400 mg BID
Grade 1 (Mild)26
Grade 2 (Moderate)410
Grade 3 (Severe)12
Grade 4 (Life-Threatening)24
Grade 5 (Death)12
SecondaryWHO Ordinal Scale

Clinical outcome assessed by WHO Ordinal Scale for Clinical Improvement. Scale is 0-8 where higher score is worse outcome.

Time frame:
30 days
Reported as:
Mean · units on a scale
WHO Ordinal Scale
units on a scalePlaceboSPI-1005 400 mg BID
WHO Ordinal Scale2.33 ± 2.422.64 ± 2.01

Adverse events

Collected over 30 days, and up to 60 days for subjects who do not show resolution of clinical status and/or laboratory results on Day 30. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/9 (11.1%)3/9 (33.3%)1/9 (11.1%)
SPI-1005 400 mg BID4/16 (25%)5/16 (31.3%)8/16 (50%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlaceboSPI-1005 400 mg BID
Acute kidney injuryRenal and urinary disorders0/93/16
SepsisInfections and infestations0/92/16
Acute myocardial infarctionCardiac disorders1/90/16
Alanine aminotransferase increasedInvestigations1/90/16
Aspartate aminotransferase increasedInvestigations1/90/16
PneumoniaInfections and infestations1/91/16
HaematomaVascular disorders1/90/16
Multiple organ dysfunction syndromeGeneral disorders0/91/16
ColitisGastrointestinal disorders0/91/16
Small intestinal haemorrhageGastrointestinal disorders0/91/16
Most frequent other events
Most frequent other events
EventPlaceboSPI-1005 400 mg BID
Gastrooesophageal reflux diseaseGastrointestinal disorders0/92/16
Acute kidney injuryRenal and urinary disorders1/92/16
HypoxiaRespiratory, thoracic and mediastinal disorders0/92/16
TracheostomySurgical and medical procedures0/92/16
Deep vein thrombosisVascular disorders0/92/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboSPI-1005 400 mg BIDTotal
Mean57.7 ± 16.754.8 ± 12.555.8 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSPI-1005 400 mg BIDTotal
Female4812
Male5813
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboSPI-1005 400 mg BIDTotal
Hispanic or Latino022
Not Hispanic or Latino91423
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboSPI-1005 400 mg BIDTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American123
White81321
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)PlaceboSPI-1005 400 mg BIDTotal
United States91625
COVID-19 Vaccination
COVID-19 Vaccination(Participants)PlaceboSPI-1005 400 mg BIDTotal
Yes448
No51217
WHO Ordinal Scale
WHO Ordinal Scale(units on a scale)PlaceboSPI-1005 400 mg BIDTotal
Mean5.44 ± 0.735.44 ± 0.635.44 ± 0.65
08

Study locations

7 sites
  • Yale University
    New Haven, Connecticut 96510, United States
  • St. Luke's Cystic Fibrosis Center of Idaho
    Boise, Idaho 83702, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66160, United States
  • Washington University in St. Louis
    St Louis, Missouri 63130, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • Wake Forest University
    Winston-Salem, North Carolina 27109, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
09

References and documents

Publications

  • Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, Duan Y, Yu J, Wang L, Yang K, Liu F, Jiang R, Yang X, You T, Liu X, Yang X, Bai F, Liu H, Liu X, Guddat LW, Xu W, Xiao G, Qin C, Shi Z, Jiang H, Rao Z, Yang H. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020 Jun;582(7811):289-293. doi: 10.1038/s41586-020-2223-y. Epub 2020 Apr 9. PubMed 32272481 ↗
  • Menendez CA, Bylehn F, Perez-Lemus GR, Alvarado W, de Pablo JJ. Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease. Sci Adv. 2020 Sep 11;6(37):eabd0345. doi: 10.1126/sciadv.abd0345. Print 2020 Sep. PubMed 32917717 ↗
  • Weglarz-Tomczak E, Tomczak JM, Talma M, Burda-Grabowska M, Giurg M, Brul S. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2. Sci Rep. 2021 Feb 11;11(1):3640. doi: 10.1038/s41598-021-83229-6. PubMed 33574416 ↗
  • Brown AS, Ackerley DF, Calcott MJ. High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor. Molecules. 2020 Oct 13;25(20):4666. doi: 10.3390/molecules25204666. PubMed 33066278 ↗
  • Haritha CV, Sharun K, Jose B. Ebselen, a new candidate therapeutic against SARS-CoV-2. Int J Surg. 2020 Dec;84:53-56. doi: 10.1016/j.ijsu.2020.10.018. Epub 2020 Oct 23. No abstract available. PubMed 33120196 ↗
  • Chen T, Fei CY, Chen YP, Sargsyan K, Chang CP, Yuan HS, Lim C. Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir. ACS Pharmacol Transl Sci. 2021 Mar 26;4(2):898-907. doi: 10.1021/acsptsci.1c00022. eCollection 2021 Apr 9. PubMed 33855277 ↗
  • Sies H, Parnham MJ. Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections. Free Radic Biol Med. 2020 Aug 20;156:107-112. doi: 10.1016/j.freeradbiomed.2020.06.032. Epub 2020 Jun 26. PubMed 32598985 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in May 2023, 20 months.

Results were first posted in Jun 2026, 3 years 1 month after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 20 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2020
First posted
Jul 23, 2020
StartActual
Aug 27, 2021
Primary completionActual
May 5, 2023
CompletionActual
Jun 6, 2023
Results first posted
Jun 29, 2026
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04483973
Lead sponsor
Sound Pharmaceuticals, Incorporated
Responsible party
Sponsor
First posted
Jul 23, 2020
Start date
Aug 27, 2021
Primary completion
May 5, 2023
Completion
Jun 6, 2023
Results posted
Jun 29, 2026
Last update
Jun 29, 2026

Study contacts

Miriam Treggiari, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ebselen

Start the discussion